Sonoma Pharmaceuticals, Inc. (SNOA) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 20 institutional investors hold a position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA).

• The collective stake of institutional investors in Sonoma Pharmaceuticals moved to 3.6% in September 2025, a shift down from the 5.7% reported for June 2025.
• Institutional share ownership changed by 78.15% QoQ, while the number of institutional owners saw an increase of 42.86% YoY.
• The latest 13F cycle for Sonoma Pharmaceuticals reveals that of 20 total investors, 10 funds grew their exposure, whereas 1 reduced theirs and 9 made no changes.
• The aggregate institutional position in Sonoma Pharmaceuticals now stands at 59.36K shares as of September 2025, after investors increased their holdings (up by 26.04K shares quarter on quarter which is up 31.57K shares year over year).
• With 20.87K shares, VANGUARD GROUP INC commands the largest institutional position in Sonoma Pharmaceuticals as of September 30, 2025, equating to 1.25% of the company.
• Among the most significant buyers of Sonoma Pharmaceuticals during September 2025 were VANGUARD GROUP INC (20.87K), DRW Securities, LLC (17.07K), CITIGROUP INC (656), Rockefeller Capital Management L.P. (646), Tower Research Capital LLC (TRC) (536).
• Leading sellers of Sonoma Pharmaceuticals stock in September 2025 included UBS Group AG (14.31K).
• The top 10 institutional holders of Sonoma Pharmaceuticals for the quarter ending September 2025 included VANGUARD GROUP INC (20.87K), GEODE CAPITAL MANAGEMENT, LLC (17.62K), DRW Securities, LLC (17.07K), Tower Research Capital LLC (TRC) (1.54K), CITIGROUP INC (656), Rockefeller Capital Management L.P. (646), Global Retirement Partners, LLC (438), MAI Capital Management (124), JPMORGAN CHASE & CO (123), BlackRock, Inc. (113).